Navigation Links
Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
Date:11/28/2007

Renowned oncologists bring decades of cancer research and clinical

development experience to Celator.

PRINCETON, N.J., Nov. 28 /PRNewswire/ -- Celator Pharmaceuticals, a biotechnology company working to develop combination chemotherapies to treat different types of cancer, today announced two recent appointments to its Scientific Advisory Board: Frederick R. Appelbaum, M.D., head of the University of Washington School of Medicine's Division of Medical Oncology and President of the Seattle Cancer Care Alliance (SCCA); and Ross C. Donehower, M.D., Professor of Oncology and Medicine at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.

Dr. Appelbaum is the author of more than 800 articles and is active on the editorial boards of many scientific journals. He is a current or former member of a number of national scientific committees including the Board of Scientific Advisors of the National Cancer Institute. Dr. Appelbaum is a graduate of Dartmouth College and of Tufts University School of Medicine. Prior to joining the faculty of the University of Washington in 1978, Dr. Appelbaum was a clinical associate and investigator with the National Cancer Institute in Bethesda, MD.

Dr. Donehower is also Director of the Division of Medical Oncology at The Johns Hopkins Oncology Center. His clinical research has focused on the treatment of gastrointestinal and lung cancers as well as new drug development. He has authored over 150 scientific publications and sits on the editorial board of numerous prestigious scientific journals. Before joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate with the National Cancer Institute. Dr. Donehower received his medical training at the University of Minnesota.

"We are delighted to welcome Dr. Appelbaum and Dr. Donehower to Celator's Scientific Advisory Board," said Andrew Janoff, Ph.D., CEO of Celator Pharmaceuticals. "Both of these talented individuals bring a depth of experience in cancer research and treatment that will be an enormous strategic asset for us as we work to develop new and more effective combination chemotherapies in the years ahead based on Celator's Ratiometric Dosing(TM) process."

About Celator

Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's technology platform, represents a revolutionary new approach to the development of combination therapies based on the principle of ratiometric dosing, where drug agents are combined and maintained in the optimal ratio to target cancer cells with maximum effectiveness. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX-571, now positioned to advance to a Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Frederick J. Ferrer Named New CEO of The Health Trust
2. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
3. Thomson Scientific Predicts Nobel Laureates
4. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
5. Thomson Scientific Announces BONDplus for Biological Researchers
6. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
7. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
10. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
11. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
Breaking Medicine Technology: